Skip to main content
. Author manuscript; available in PMC: 2017 Mar 30.
Published in final edited form as: Pharmacotherapy. 2016 Jun;36(6):617–622. doi: 10.1002/phar.1759

Table 1.

Demographics

Pre-IDMS
n=63		 Post-IDMS
n=95		 p-value
Age, median yrs (range)   65 (30–90)   62 (19–84) 0.09
Sex, female   41 (65%)   55 (57%) 0.365
Race
 White   43 (68%)   62 (65%)
 Black   15 (24%)   26 (27%)
 Hispanic    0 (0%)    3 (3%)
 Asian    4 (6%)    3 (3%)
 Other    1 (%)    1 (1%)
Height, median, cm (range) 168 (145–188) 168 (152–196) 0.168
Weight, median, kg (range)   71 (42–124)   75 (46–153) 0.018
Albumin, median g/dl (range)  3.7 (1.7–4.7)  3.7 (2.2–4.8) 0.24
Malignancy
 Breast   12 (19%)   12 (13%)
 Lung   26 (41%)   50 (52%)
 Ovarian    9 (14%)   10 (11%)
 Other   16 (26%)   23 (24%)
Other chemotherapy
 Paclitaxel   27 (43%)   41 (43%)
 Pemetrexed   11 (17%)   17 (18%)
 Docetaxel   15 (24%)   21 (22%)
 Etoposide   10 (16%)   10 (11%)
 Other    0 (0%)    2 (2%)
 None    0 (0%)    1 (1%)

IDMS = isotope dilution mass spectrometry.